Transcription of STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
{{id}} {{{paragraph}}}
Example: bankruptcy
STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
Working document January 2017. Draft document for comment 1 STABILITY TESTING OF ACTIVE . 2 PHARMACEUTICAL ingredients AND. 3 finished PHARMACEUTICAL PRODUCTS. 4 (January 2017). 5 DRAFT FOR COMMENT. Should you have any comments on the attached text and the STABILITY conditions for WHO Member States (MS) by Region, appendixed to the previous version of this guidance ( ), please send these to: Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: fax: (+41 22) 791 4730;. and to Mrs Ksenia Finnerty by 15 March 2017.
Working document QAS/17.694 January 2017 Draft document for comment 1 STABILITY TESTING OF ACTIVE 2 PHARMACEUTICAL INGREDIENTS AND 3 FINISHED PHARMACEUTICAL PRODUCTS ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
A Stability Testing Guidelines:, Stability testing, Q1A(R2) Guideline Stability Testing of New, Stability testing Guidelines, Stability Testing of Pharmaceutical, Stability testing of pharmaceutical products, Guidelines, Stability testing of active pharmaceutical, Stability, BRACKETING AND MATRIXING DESIGNS FOR, BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING, GUIDELINES ON STABILITY TESTING OF COSMETIC, GUIDELINES ON STABILITY TESTING OF COSMETIC PRODUCTS, Stability Testing of new Drug, STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS, GUIDELINES ON STABILITY EVALUATION OF